Abstract
Many pharmaceuticals on the market suffer from two significant limitations to their activity: lack of specificity toward the pathological site and poor aqueous solubility. Both factors therefore require the application of a large total dose of a drug to achieve high local concentration, causing numerous off-target toxic effects. Consequently, the grand aim of targeted drug delivery - the often-referred “magic bullet” - promises to improve drug concentration at the target site and maximize therapeutic response. Nanomaterial drug delivery systems have been explored extensively in the recent years for just this purpose. In the field of medicine, nanocarriers (NCs) have the potential to improve the biodistribution and pharmacokinetic characteristics of drugs, thereby reducing side effects while improving the therapeutic effect of drugs. Many nanomaterials are exquisitely designed and possess potent properties, yet it is extremely important to note that a general understanding of the interaction of nanomaterials with biological systems is essential for any such model properties to be effective in vivo, since the body presents a host of biological ‘barriers’ that will be encountered drug NCs. This review offers a general overview of the different biological obstacles that a NC must negotiate before it can carry out its desired role as a medicinal agent. From this standpoint we suggest aspects that should be considered for the rational design of novel nanomaterials possessing physicochemical properties that are appropriate for therapeutic or theragnostic applications.
Keywords: Nanomedicine, nanocarrier, biological barrier, passive targeting, drug specificity, vascular endothelium.
Current Medicinal Chemistry
Title:The Fate of Nanocarriers As Nanomedicines In Vivo: Important Considerations and Biological Barriers to Overcome
Volume: 20 Issue: 22
Author(s): M. Moros, S. G. Mitchell, V. Grazu and J.M. de la Fuente
Affiliation:
Keywords: Nanomedicine, nanocarrier, biological barrier, passive targeting, drug specificity, vascular endothelium.
Abstract: Many pharmaceuticals on the market suffer from two significant limitations to their activity: lack of specificity toward the pathological site and poor aqueous solubility. Both factors therefore require the application of a large total dose of a drug to achieve high local concentration, causing numerous off-target toxic effects. Consequently, the grand aim of targeted drug delivery - the often-referred “magic bullet” - promises to improve drug concentration at the target site and maximize therapeutic response. Nanomaterial drug delivery systems have been explored extensively in the recent years for just this purpose. In the field of medicine, nanocarriers (NCs) have the potential to improve the biodistribution and pharmacokinetic characteristics of drugs, thereby reducing side effects while improving the therapeutic effect of drugs. Many nanomaterials are exquisitely designed and possess potent properties, yet it is extremely important to note that a general understanding of the interaction of nanomaterials with biological systems is essential for any such model properties to be effective in vivo, since the body presents a host of biological ‘barriers’ that will be encountered drug NCs. This review offers a general overview of the different biological obstacles that a NC must negotiate before it can carry out its desired role as a medicinal agent. From this standpoint we suggest aspects that should be considered for the rational design of novel nanomaterials possessing physicochemical properties that are appropriate for therapeutic or theragnostic applications.
Export Options
About this article
Cite this article as:
Moros M., Mitchell G. S., Grazu V. and Fuente la J.M. de, The Fate of Nanocarriers As Nanomedicines In Vivo: Important Considerations and Biological Barriers to Overcome, Current Medicinal Chemistry 2013; 20 (22) . https://dx.doi.org/10.2174/0929867311320220003
DOI https://dx.doi.org/10.2174/0929867311320220003 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
in vitro Anti-leukaemia Activity of Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs)
Recent Patents on Anti-Cancer Drug Discovery The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines
Letters in Drug Design & Discovery Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke
Current Drug Targets Chartreusin, Elsamicin A and Related Anti-Cancer Antibiotics
Current Medicinal Chemistry - Anti-Cancer Agents Inhibition of V-ATPase and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes
Current Pharmaceutical Design Synthesis and Anti-cancer Activity of 3-substituted Benzoyl-4-substituted Phenyl-1H-pyrrole Derivatives
Anti-Cancer Agents in Medicinal Chemistry Topics of Physiological and Pathophysiological Functions of Lymphatics
Current Molecular Medicine Improvement of Adoptive Cellular Immunotherapy of Human Cancer Using Ex-Vivo Gene Transfer
Current Gene Therapy Coronary CT Angiography in the Diagnosis of Coronary Artery Disease
Current Medical Imaging Editorial (Thematic Issue: Melanoma Treatment: Finally Some Light at the End of the Tunnel?)
Clinical Cancer Drugs Evolution of Molecular Targets in Melanoma Treatment
Current Pharmaceutical Design Editorial [Hot topic: Recent Progress in Cancer Therapeutics (Guest Editor: Kurt S. Zaenker)]
Current Molecular Medicine Effects of Anticancer Drugs in Reproductive Parameters of Juvenile Male Animals and Role of Protective Agents
Anti-Cancer Agents in Medicinal Chemistry Effect of Prostaglandins on the Regulation of Tumor Growth
Current Medicinal Chemistry - Anti-Cancer Agents Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Anti-proliferative and Apoptosis Induction Activity of Rhizome Extracts of <i>Paris polyphylla</i> Smith on Oral Cancer Cell
Current Cancer Therapy Reviews Research Advances in the Treatment of Melanoma by Treat Melanoma
Current Topics in Medicinal Chemistry Dehydroleucodine Induces a TP73-dependent Transcriptional Regulation of Multiple Cell Death Target Genes in Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry The Molecular Targets of Antitumor 2-deoxycytidine Analogues
Current Drug Targets PET in Anti-Cancer Drug Development and Therapy
Recent Patents on Anti-Cancer Drug Discovery